Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
Lecanemab is the first therapy of its kind approved in the EU that could potentially slow the progression of Alzheimer’s disease. The use of lecanemab will now be considered by national payers, who will assess the treatment against further nationally determined criteria.
This comes as the Appeals board of the European Commission were unable to reach a verdict following the “no opinion” decision of the Standing Committee on Medicinal Products for Human Use and the European Commission. The matter will now be referred the European Commission for a final decision.
Results from the world’s largest survey reveals that stigma around dementia is preventing people from seeking the information, advice, support and medical help.
Alzheimer’s Disease International (ADI) and the Pan American Health Organization (PAHO) launch an Americas-wide campaign around raising awareness of Alzheimer's disease and other types of dementia.
Dementia was specifically recognised as a global health priority by G20 leaders in the declaration of the Osaka Summit, providing much needed global attention from G20 countries.
The Canadian government has announced their adoption of a national plan on dementia.
Teacher Yasmin Jeevanjee tells her story as a care partner in Kenya.
A paper published in the journal Brain has identified a brain disorder, known as LATE, which appears to mimic the clinical features of Alzheimer’s disease.
A message from ADI as 2018 comes to a close and what we look forward to in 2019.
Her Majesty Queen Silvia of Sweden has become an Honorary Ambassador of Alzheimer’s Disease International (ADI), in recognition of her personal commitment to work surrounding elderly and end of life care, and specifically dementia. Queen Silvia has a long-standing association with and in support of dementia. In 1996, she initiated…